Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × sacituzumab govitecan × Clear all

Status

Recruiting 55 Active not recruiting 24 Not yet recruiting 10 Completed 10 Terminated 3 Withdrawn 1 Unknown 1 Enrolling by invitation 1 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Afatinib 3 3-Iodobenzylguanidine 3 niraparib 2 lenvatinib 2 ibrutinib 2 gallium 68 PSMA-11 2 abemaciclib 2 Trastuzumab 2 Magnetic Resonance Spectroscopy 2 Gefitinib 2 Amifampridine 2 Abiraterone Acetate 2 zenocutuzumab 1 vorasidenib 1 tucatinib 1 trilaciclib 1 tovorafenib 1 talquetamab 1 tafasitamab 1 selpercatinib 1 sacituzumab govitecan 1 ripretinib 1 ponatinib 1 pomalidomide 1 pirtobrutinib 1 pertuzumab 1 olaratumab 1 olaparib 1 nilotinib 1 motexafin gadolinium 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04320693 2021-08-19

Expanded Access for IMMU-132

Gilead Sciences

Approved for marketing

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡